ACRV
Acrivon TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Acrivon can re-rate if ACR-368 stays on the stated Phase 3 path and the second-half 2026 interim update supports the signal, while runway into Q3 2027 keeps financing pressure manageable.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Dilution or financing overhang persists despite runway into Q3 2027, especially given the company's small market cap and development-stage profile.
Momentum
88
Value
58
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.45 · Bull $3.20 · Bear $0.75
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $11.50
Why
Momentum88 · Δ7d -
Value58 · Δ7d +0.1
Sentiment58 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
88
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.3
Sentiment
58
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 87.8 / Value 57.7 / Sentiment 58.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$66.77M
Beta
-
Shares Out
31.56M
P/E (TTM) · Derived
-0.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.19
Rev YoY
-
EPS YoY
+19.7%
Gross Margin
-
Op Margin
-
Net Debt
-$179.48M
Current Ratio
8.75
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology